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Stomatococcus mucilaginosus septicemia 
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Objective: To report an unexpectedly high number of cases of septicemia with Stomatococcus mucilaginosus, and try 
to identify predisposing factors. 
Methods: All blood cultures obtained during 1991-93 from patients treated at the hematologic ward were 
bacteriologically identified. The medical records of patients with S. mucilaginosus-positive blood cultures were 
retrospectively reviewed and evaluated. The antibiotic susceptibility pattern and restriction fragment length 
polymorphism (RFLP) of S. mucilaginosus were tested. 
Results: S. mucilaginosus blood isolates from patients with hematologic malignancies were found to be as common 
as isolates of Staphylococcus aureus. Eleven patients with myelogenous leukemia and isolation of S. mucilaginosus 
from the blood are reported on. One patient had concomitant meningitis. All patients were neutropenic and most had 
oral mucositis and had been given ciprofloxacin prophylaxis. S. mucilaginosus isolates from these patients were 
resistant to ciprofloxacin in contrast to isolates from patients who had received other prophylactic regimens and seven 
isolates found in healthy individuals not recently treated with antibiotics. The resistant S. mucilaginosus were found to 
be of diverse genetic origin as determined by RFLP. 
Conclusions: The appearance of resistant strains during ciprofloxacin prophylaxis may be a predisposing factor for S. 
mucilaginosus septicemia. There was no evidence of a nosocomial spread of S. mucilaginosus strains. 
Key words: Stomatococcus mucilaginosus, septicemia, ciprofloxacin resistance, neutropenia, restriction fragment 
length polymorphism, antibiotic prophylaxis 
INTRODUCTION 
Intensive chemotherapy for acute leukemia regularly 
causes neutropenia, making the patients susceptible to 
bacterial and fungal infections [l]. During the last two 
decades a change in the spectrum of organisms respons- 
ible for infections in neutropenic patients has been 
reported [2]. Gram-positive bacteria such as viridans 
streptococci and multiresistant coagulase-negative 
staphylococci are now the predominant cause of these 
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infections, replacing Gram-negative bacteria, which 
were the most prevalent species during the 1970s [3,4]. 
The reason for this shift is not fully understood, but the 
wider use of indwelling catheters, as well as the use of 
certain cytotoxic agents, may be contributing factors. 
An increased incidence of alpha-hemolytic strepto- 
coccal septicemia has been reported after treatment 
with high doses of cytosine arabinoside [5,6]. Also, the 
introduction of prophylactic regimens often containing 
fluoroquinolones has been suggested as a cause of this 
shift [7,8]. 
Stomatococcus mucilaginosus is a Gram-positive coccus 
which is a normal inhabitant of the human oral flora. 
It was first described as causing infection in 1978, when 
Rubin et al. reported a patient with endocarditis [9]. 
Since 1982, when it was described as a new genus [lo] 
there have been sporadic reports of cases with invasive 
disease, e.g. endocarditis and catheter-related septicemia 
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[l l] .  In the last 4 to 5 years reports have begun to 
accumulate regarding S. mucilaginosus as a pathogen in 
neutropenic patients [12-151. In an attempt to find 
predisposing factors common in patients affected by 
this pathogen and to see if the occurrence of S. 
mucilaginosus septicemia seen in the hematologic ward 
was caused by a nosocomial spread of a specific S. 
mucilaginosus strain, we retrospectively studied 1 1 
leukemic patients with S. mucilaginosus septicemia, 
including one patient with concomitant meningitis. 
MATERIAL AND METHODS 
Patients 
AU blood cultures obtained during 1991-93 from 
patients treated at the hematologic ward at the 
Department of Internal Medicine, Umei University 
hospital were bacteriologically identified. The medical 
records of the patients with S. mucilaginosus-positive 
blood cultures were retrospectively reviewed and 
evaluated. Neutropenia was defined as an absolute 
neutrophil count (ANC) of <0.5 X 109/L. Temperature 
was measured by digital axillary thermometer at  least 
twice daily. Fever was defined as a body temperature of 
238.5 "C or two consecutive measurements of 238  "C 
within 12 h. Resolution of fever was defined as two 
consecutive measurements of 537.5 "C. 
Healthy individuals 
Samples from tonsils and gingiva were taken with a 
cotton swab from 10 healthy individuals without 
antibiotic treatment, attending the Department of 
Infectious Diseases for vaccination. The samples were 
cultivated on blood agar and hematin agar plates and 
incubated for 18 h at 37 "C in air, and in 5% COz, 
respectively. From the mixed flora obtained on the 
plates, transparent-to-white, mucoid, convex colonies 
were isolated. The colonies were identified as S. 
mucilaginosus and tested for antibiotic susceptibility as 
described in the bacterial strain section. 
Blood cultures 
Ten milliliters of blood was divided into one aerobic 
and one anaerobic diphasic bottle (Laboratory of 
Clinical Bacteriology, Sundsvall Hospital, Sweden). 
This was repeated once or twice within a few hours, 
giving a total yield of 20-30 ml of blood. The bottles 
were incubated for 10 days and read twice daily by 
ocular inspection. Bottles showing visible growth on 
the agar slant, hemolysis, or turbidity in the broth were 
subcultured on blood agar, hematin agar, and, if growth 
in the anaerobic bottle was seen, also on brain-heart 
infusion agar plates. 
Bacterial strains 
The first blood isolate of S. mucilaginosus found was 
sent to Prof. Tom Bergan, Rikshospitalet, Oslo, for 
confirmation. The rest of the stomatococcal strains 
were identified by microscopic and colonial character- 
istics together with s. mucilaginosus ATCC 25296. s. 
mucilaginosus had transparent-to-white, mucoid, convex 
colonies. All strains grew well on hematin agar 
incubated in 5% CO2 and were negative in routine slide 
test for catalase. A test panel originally developed for 
viridans streptococci [16], testing glycosidase activities 
with 4-methylumbelliferyl-linked fluorogenic sub- 
strates and conventional fermentation tests, resulted in 
positivity only in alpha- and beta-glucosidase. In Api 
20 STREP (bioMtrieux, Marcy-l'Etoile, France) the 
code for S. mucilaginosus ATCC 25296 was 5140010. 
The isolated strains had the codes 5140010 (four 
strains), 5150010 ( s i x  strains) 5150000 (one strain) or 
5170010 (nine strains). There was no biochemical 
diversity among the strains from healthy and septicemic 
individuals. 
Antibiotic susceptibility testing 
Overnight cultures in Todd-Hewitt broth, diluted 1/50 
in physiologic saline, were used for susceptibility 
testing. Blood agar plates were swabbed with the saline 
suspension and then incubated with E-test strips (Al3 
Biodisk, Stockholm, Sweden). The plates were 
incubated for 18 h in 5% CO2. 
Restriction fragment length polymorphism (RFLP) 
Chromosomal DNA for pulsed-field gel 
electrophoresis (PFGE) was obtained by modifications 
of previously described methods [17,18]. Briefly, 
750pL of an overnight culture with stomatococci 
grown in 5 mL of Todd-Hewitt broth (Difco, Detroit, 
Michigan, USA) incubated in 5% CO2 was centrifuged 
and resuspended in 1OOpL of TBE buffer (45mM 
Tris-HC1, 45 mM borat, 1.0 mM EDTA, pH 8.3). The 
samples were warmed to 50 "C and 4 pL of lysozyme 
(25 mg/mL, Sigma Chemical Co., St Louis, Mo., 
USA), 4 pL of mutanolysin (5000 U/mL, Sigma) and 
100 pL of 50 "C 2% agarose (Bio-Rad Laboratories, 
Hercules, California, USA) were added. The mixtures 
were pipetted into plug molds and the agarose was 
allowed to solidie. The plugs were placed in 1 d of 
EC (lysis) buffer (6 mM Tris-HC1 [PH 7.61, 1 M NaC1, 
100 mM EDTA [PH 7.51, 0.5% Brij-58, 0.2% 
deoxycholate, 0.5% sodium lauroyl sarcosine) [18] with 
40pL of lysozyme (25mg/mL) and 40pL of 
mutanolysin (5000 U/mL) and were incubated for 
3.5 h a t  37 "C. After washing in 2 mL of TE wash 
buffer (10 mM Tris-HC1, 1 mM EDTA b H  7.6]), 
40 pL of proteinase K (25 mg/mL, Boehringer 
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Mannheim, Indianapolis, Indiana, USA) and 1 mL of 
EDTA solution (0.5 M EDTA [pH 7.61 and 0.5% 
sodium lauroyl sarcosine) were added [17] and the plugs 
were incubated overnight at  50°C. After washing in 
TE wash buffer, proteinase K was inactivated with 
10 pL/mL of 100 mM phenylmethylsulfonyl fluoride 
for 1 h at  room temperature. The washing was then 
repeated three times. For PFGE, DNA was restricted 
with VspI (MBI Fermentas, Vilnius, Lithuania) 25 U 
per plug, in restriction buffer (50 mM Tris-HC1 [PH 
7.51, 10 mM MgC12, 100 mM NaCl, 0.1 mg/mL 
bovine serum albumin) at  37 "C overnight. After 
incubation, slices of the plugs were loaded into wells of 
1.25% agarose gels in 0.5 XPFGE buffer. Succharomyces 
rerevisiae chromosomal DNA (Bio-Rad) was used as 
standard. Electrophoresis was performed with a 
Contoured-Clamped Homogeneous Electric Field 
apparatus (Gene Path System, Bio-Rad) using the 
program for Staphylococcus aureus for 20 h. Gels were 
stained with ethidium bromide and photographed 
under UV illumination. 
RESULTS 
In the 3-year study period, 1991-93, a total of 5444 
blood cultures was drawn from indoor patients at the 
hematologic ward, each comprising two bottles. In 
total, 229 blood culture-positive episodes from 149 
patients were identified (Table 1). The growth of all 
bacteria or yeast recovered in blood cultures from a 
patient within the same week is referred to as an 
episode. O f  the isolated microorganisms, 148 (57%) 
were Gram-positive aerobic/facultative anaerobic 
organisms. S. muciluginosus was found in 11 (4%) 
episodes. The bacteria most commonly considered as 
contaminants in blood cultures are: coagulase- 
negative staphylococci, Corynebacterium species, and 
Propionibucterium [19,20]. Ifepisodes with growth of any 
of these species, in only one out of four to six bottles 
from a patient, were excluded, the stomatococci 
accounted for 9% of the aerobic/facultative anaerobic 
Gram-positive species found. 
Patients 
During the observation period, S. muciluginosus were 
isolated from the blood of 11 patients with 
myelogenous leukemias, including one patient with 
concomitant meningitis. There were seven males and 
four females with a median age of 45 years (range 26 
to 77 years). Individual patient characteristics are 
summarized in Table 2.. At the time of S. muciluginosur 
septicemia, all patients had profound neutropenia 
(ANC <O. 1 X lO'/L) due to intensive combined 
chemotherapy, including cytosine arabinoside com- 
Table 1 
229 episodes of septicemia in patients with hematologic 
malignancies in Umei, Sweden, during 1991-93 
Distribution of 258 microorganisms causing 
No. 'XI of all strains 
Aerobic/facultative ailderobic species 
(;rani-negattve strains 
E .  roli 
Klebsielia 
Entertibarter 
Pseudomonas aeriqinusa 
Citvoharrer 
Others 
Subtotal 
Gram-positive strains 
Coaguldse-negative 
staphylococci 
Viridans streptococci 
Corynebarteriuni 
Srapirylococrits aureus 
Storrratococr~s m n r i l a g i m w  
Pneumococci 
Others 
Subtotdl 
16 
16 
9 
4 
14 
64 
3 
72(51,') 
22 
12 
11 
8 
10 
148 
13(8.') 
6 
6 
3.5 
2 
1 .5 
5 
25 (3 1 1') 
28 
8.5 
5 
5 
4 
3 
4 
57(591') 
Anaerohic species 
Propionibacteria 29(3.') 1 I .2 
CIostridiirm spp. 4 125 
Others 3 1 
Subtotal 36(10") 14(5") 
Yeast 
Candida aibiraru h 2 
Candida glabruta 4 I .5 
Subtotal 10 4(5h) 
T h e  numbers in the  perentheses represent the number '  and the 
percentagc" o f  all strains after exclusion of comnion c o t ~ t a i i ~ i n m t ~ .  
bined with amsacrine-etoposide (patients no. 2, 5, 8, 9 
and lo), mitoxantrone (patients no. 1 and l l ) ,  or 
daunorubicin-idarubicin (patients no. 3, 4, 6 and 7). 
The duration of neutropenia preceding the septicemia 
ranged from 5 to 19 days (median 10 days). 
AU patients had indwelling intravenous catheters. 
Seven patients had clinical signs of oral mucositis, 
esophagitis, or gastritis (Table 2). All but one patient 
received oral prophylactic antibacterial treatment; nine 
patients received ciprofloxacin, one of them also 
trimethoprim-sulfamethoxazol, and one patient 
trimethoprim-sulfamethoxazol only (Table 2). Most 
patients also received oral antifungal and antiviral 
prophylaxis. None of the patients received H2- 
antagonist therapy. 
Treatment and outcome 
The initial antibiotic treatment varied considerably as 
indicated in Table 2. Vancomycin was given within 
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Table 2 Characteristics of 11 patients with S. muciluginosus septicemia 
Patient no. 1 
F/35 
2 3 4 
M/31" F/42 M/26 
CML AML CML 
5 6 7 8 9 10 11 
Sexlage (years) MI77 MI76 M/29 MI73 M/45 F/57 F/50 
Diagnosis AML AML RAEBT AML AML AML AML AML 
Anitbacterial 
prophylaxis 
Cipro- 
floxacin 
Cipro- Cipro- Cipro- 
floxacinh floxacin floxacin 
Cipro- Cipro- Cipro- 
floxacin floxacin floxacin 
Cipro- None 
floxacin 
Cipm- TMP/ 
floxacin SMZ 
Days of 
neutropenia 
prior to 
septicemia 
>12 13 10 19 7 8 > I 2  > 7  5 12 7 
Mucocutaneous 
1 e s i o n s 
Gingivitis 
Gastro- 
esophagitis 
Oral Sore 
muscositis throat 
Oral Oral 
mucositis mucositis 
Esophagitis 
Gastritis Subcu- 
taneous 
catheter 
bleeding 
Gingivitis 
Initial treatment 
(within 48 h) 
Imipenem 
Vanco- 
mvcin 
Vanco- Imi- Imi- 
mycin penem penem 
Vanco- 
mycin 
Cefta- Cefia- Cefta- 
zidime zidime zidime 
Vanco- Vanco- Vanco- 
mycin mycin mycin 
Im- Cefia- 
penem zidime 
Ampho- 
tericin B 
Cef- Pipera- 
pirome cillin 
Vanco- Amikacin 
mycin 
Abbreviations: F = female; M = male; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; RAEBT = refractory 
anemia in excess of blasts in transformation; TMP/SMZ = trimethoprim-sulfamethoxazole. 
"Patient with concomitant meningitis. bCiprofloxacin replaced by TMPISMZ 2 weeks before the septicemia. 
48 h after onset of fever in 7/11 patients, and was 
subsequently added (day 3 to 8) after the results of the 
blood culture in the remaining four patients were 
obtained. The overall response to proper antibiotic 
treatment was slow, and fever persisted for a median of 
16 days (range 7 to 35 days). The duration of fever was 
s d a r  in the groups given initial or delayed treatment 
with vancomycin. Due to the long duration of the 
fever, addition of antifungal therapy (amphotericin B) 
was made in seven of the patients. Only one patient had 
any sign of fungal infection (oral and esophagal 
candidiasis). No fungi were found in the blood culture. 
Repeated blood cultures were done in most patients, 
but were all sterile. In two patients, the indwelling 
intravenous catheter was removed; cultures from the 
tips were both negative. None of the remaining patients 
had recurrent S. mucilaginosus bacteremia after 
resolution of fever. The septicemic condition of patient 
no. 2 was complicated by meningitis with progressive 
headache and nuchal rigidity. S. mucilaginosus could be 
isolated in the cerebrospinal fluid on day 14 in spite of 
treatment with vancomycin and cefotaxime in a dose 
usually given for treatment of meningitis. The patient 
died, stdl febrile, 22 days after onset of fever. At follow- 
up in December 1994, 10/11 patients had died 
between 19 to 550 days (median 162.5 days) after the 
S. mucilaginosus septicemia; however, only one death 
(no. 2) directly related to the S. mucilaginosus septicemia 
episode. One patient (no. 4) is stdl alive 600 days after 
the infection. 
S. mucilaginosus in healthy individuals 
Stomatococci were isolated from gingival and tonsillar 
regions in 7/10 healthy individuals. In three cases the 
S. mucilaginosus organisms were only found in the 
gingival sample and in one case only in the throat 
culture. 
Antibiotic susceptibility 
The minimum inhibitory concentrations (MICs) of all 
tested antibiotics were lower for S. mucilaginosus isolated 
from the healthy individuals than for those fiom the 
blood isolates from the patients (Table 3). The 
difference was statistically significant for cefuroxirne 
(pCO.05) and for ciprofloxacin (p<O.OOl ,  Mann- 
Whitney U-test). The MICs for ciprofloxacin for S. 
mucilaginosus ranged fiom 0.25 to 0.5 mg/L in isolates 
from healthy individuals. Only two patients had strains 
with MICs for ciprofloxacin of 0.5 mg/L. These two 
strains were from patients (nos 9 and 11) not given 
ciprofloxacin as prophylaxis. The patients who had 
received ciprofloxacin as prophylaxis had MICs ranging 
from 3 to >32 mg/L (Table 3). No common antibiotic 
resistance pattern could otherwise be revealed in the 
strains isolated fiom the bacteremic patients. 
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Table 3 
hematologic patients compared to MICso of seven colonizing strains from throat and gingiva of healthy individuals 
MICso (mg/L) of twelve strains of S. mucilaginosus isolated from blood and cerebrospinal fluid (CSF) from 
Hematologic patients Healthy individuals 
Blood/CSF isolates Throat/gingival isolates 
MICm MIC range MICv, MIC range 
Cefotaximc 0.12 10.016-1.5 0.016 0.0050.06 
Vanc omy cin 1.5 0.5-1.5 0.75 0.5-1.0 
Cefuroxinie 0.12 10.016-2.0 0.016 1 0.0 1 6-0.06 
Penicillin G 0.02 10.016-1.5 0.016 0 .O06&0.0 16 
Centmiicin 6 3-8 3 2-4 
Trimethoprim-sulfdmethoxazole 0.06 0.02-4 0.05 0.02-0.12 
Ciprofloxacin 12 (0.5")3 to >32 0.38 0.25-0.5 
"MIC of strains from patients no. 9 and no. 11, not receiving ciprofloxacin prophylaxis. 
Restriction fragment length polymorphism 
Digestion with restriction enzyme VspI demonstrated 
distinct cleavage patterns in all the S .  mucilaginosus 
strains (Figure 1). No corresponding phenotypic 
diversity was found in the biochemical tests used. The 
two isolates from blood and cerebrospinal fluid of 
patient no. 2 had identical restriction patterns. Except 
for these two strains, a common pattern was found 
neither between the highly resistant strains with MIC 
>32 mg/L nor between the susceptible strains (Figure 
1). 
DISCUSSION 
In a retrospective study of the etiology behind bacterial 
septicemia in the hematologic ward, we found S. 
mucilaginosus as a common cause of septicemia in a well- 
defined population of patients with hematologic 
malignancies. All patients were severely neutropenic, 
had indwelling intravenous catheters and had received 
intensive cytotoxic therapy includmg cytosine arabino- 
side. The majority of patients also had signs of oral 
mucosal lesions and had been treated prophylactically 
with ciprofloxacin. 
Ciprofloxacin has been used in selected patients as 
a prophylactic agent in our hematologic ward during 
the last 5 years. Several reports of S. mucilaginosus 
infections have described a high proportion of fluoro- 
quinolone resistance in S. mucilaginosus strains isolated 
from hospitalized patients [21,22]. This corroborates 
our findings. In contrast, we found that the isolates 
from healthy individuals and from those patients who 
had not received ciprofloxacin prophylaxis were sensi- 
tive to ciprofloxacin. This indicates that the reported 
fluoroquinolone resistance is not caused by inherent 
resistance of these strains. Fluoroquinolones act on 
Figure 1 
electrophoresis. Lane 1 represent the strain isolated from blood from patient no. 1.  Lanes 2 and 3 contain the blood and the 
cerebrospinal fluid isolate from patient no. 2. Lanes 4 to 10 and 12 to 13 represent strains isolated from blood from patients 
no. 3 to no. 11. Lanes 11 and 21 are the Sacchavomyces cerevisiae standard (Biorad). Lanes 14 to 20 represent the colonizing S. 
wrncilaginosus strains from healthy individuals. 
Fragment patterns of the S. mucilnginosus genome restricted with VspI analyzed by pulsed-field gel 
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bacteria by altering the association of DNA gyrase 
(topoisomerase type 11) with DNA, a process required 
for DNA supercoiling [22,23]. Resistance to quino- 
lones in staphylococci, which form another genera 
of the family Micrococcaceae has primarily been 
attributed to chromosomal mutations in the DNA 
gyrase gene gyrA [24]. There are no reports of clinically 
isolated strains with plasmid-encoded quinolone 
resistance [22,25]. The diverse antibiotic sensitivity 
pattern, as well as the RFLP banding pattern, showed 
that the resistant S. mucilaginosus isolates were not 
derived from a single clone. AU patient strains revealed 
restriction enzyme patterns which were as diverse as 
those found in S. mucifaginorus isolated from healthy 
individuals. Taken together, these observations indicate 
that the antibiotic treatment of the individual patients 
accounted for the development of resistant strains 
rather than a nosocomial spread. 
The persistence of fever in spite of seemingly 
adequate antibiotic treatment is in accordance with 
other reports 1121. The indwelling intravenous catheter 
was removed in only a minority of the patients. Due to 
the prolonged fever this could have been an appropriate 
measure. However, after resolution of fever none of the 
surviving patients had recurrent S. mucilaginosus bac- 
teremia, and cultures from extracted catheters were 
negative. Thus, a catheter-related infection as an 
explanation of the prolonged fever is less likely. 
The S. mucilaginosus infections have subsequently 
resolved in most cases and the mortality associated with 
S. mucilaginosus septicemia is predominantly seen in 
patients with concomitant meningitis. McWhinney et 
al. [12] reviewed 19 cases of systemic infection with S. 
mucilaginosus from the literature in addition to data 
from eight neutropenic patients with S. mucilaginosus 
septicemia. Together with our cases, this comprises 38 
patients. Five deaths assigned to the S. mucilaginosus 
infection (13% mortality) are reported among those 
patients. Three of the five cases were associated with 
meningitis. 
Little is known about the virulence properties of 
S. mucilaginosus. The case reports of infections caused 
by S. mucilaginosus indicate it to be an opportunistic 
pathogen. The lesions of the mucous membranes often 
seen in the neutropenic patients could facilitate the 
stomatococcal entrance into the bloodstream.The 
emergence of resistant strains during ciprofloxacin 
prophylaxis may favor the growth of stomatococci in 
the oral cavity over bacterial species sensitive to 
ciprofloxacin. However, two of the patients displayed 
stomatococcal septicemia without prior ciprofloxacin 
treatment, indicating that other factors are also of 
importance for the pathogenicity of stomatococci. 
The emergence of quinolone resistance among S. 
aureus and coagulase-negative staphylococci after quin- 
olone treatment is a matter of great concern [26]. The 
data presented in this report, showing stomatococci as 
a relatively common cause of septicemia in neutropenic 
patients as well as the high tendency to acquire 
ciprofloxacin resistance, adds to this concern. A 
continued recognition of the problem, and evaluation 
of alternative regimens for prophylaxis which include 
Gram-positive bacteria, should be pursued, especially 
for such high-risk groups as neutropenic patients. 
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